The contribution of clinical pharmacology surrogates and models to drug development - A critical appraisal

British Journal of Clinical Pharmacology

Volumn 44, Issue 3, 1997, Pages 219-225

  Rolan, Paul ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Drug development; Models; Surrogates; Validation

Indexed keywords

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DECISION MAKING; DRUG COST; DRUG DEVELOPMENT; DRUG DOSE; DRUG INDUSTRY; DRUG SCREENING; HUMAN; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS;

EID: 0030884335     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00583.x     Document Type: Review

References (40)

1. Toon S. Relevance of pharmacokinetic studies in volunteers. Clin Pharmacokinet 1993; 25: 259-262.
2. Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurol 1995; 45 Suppl 7: S5-9.
3. Posner J. Exploratory development. In The Textbook of Pharmaceutical Medicine, Second Edition, eds Griffin JP, O'Grady J, Wells FO. Belfast: Queens University of Belfast, 1994: 291-314.
4. Lipicky RJ, Packer M. Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 1993; 22 (Suppl A): 179A-184A.
5. Rolan PE. General characteristics of clinical surrogates. In Advances in Headache Research Vol 5: Experimental headache models, eds Olesen J, Moskowitz M, New York: Lippincott-Raven, 1995: 27-32.
6. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 1989; 8: 415-425.
7. Fagan TC. Calcium antagonists and mortality. Another case of the need for clinical judgement. Arch Int Med 1995; 155: 20.
8. Prentice R. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440.
9. Boissel J-P, Collet J-P, Moleur P, et al. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
10. Sim J, Arnell P. Measurement validity in physical therapy research. Phys Ther 1993; 73: 102-115.
11. Marwick C. Trials reveal no benefit, possible harm of beta carotene and vitamin A for lung cancer. JAMA 1996; 275: 6.
12. Nasser SM, Bell GS, Hawksworth RJ, et al. Efficacy of the 5-lipoxygenase inhibitor ZD 2138 on allergen-induced early and late responses. Thorax 1994; 49: 743-748.
13. Howden CW, Burget DW, Hunt RH. Appropriate acid suppression for optimal healing of duodenal ulcer and gastrooesophageal reflux disease. Scan J Gastroenterol - Supplement 1994; 201: 79-82.
14. Cantor SB. Decision analysis: theory and application to medicine. Prim Care 1995; 22: 261-270.
15. Gray SJ, Rolan PE, Posner J. Effect of i.v. BW443C in cold air-induced broncoconstriction in healthy volunteers. Abstract for 4th World Conference on Clinical Pharmacology and Therapeutics, July 1989.
16. Gray SJ, Rolan PE, Phillips SC, Posner J. Acute tolerance, effects on spirometry and systemic absorption of nebulised 443C81 in healthy volunteers and asthmatic patients. Abstract for British Thoracic Society, July 1990.
17. Gray SJ, Rolan PE, Posner J. Effect of inhalation of a novel enkephalin analogue (443C81) on the response to cold air and metabisulphite challenge in healthy volunteers. Br J Clin Pharmacol 1991; 32: 662-663.
18. Phillips SC, Rolan PE, Gray SJ, Posner J. Effect of i.v. infusion of a novel enkephalin analogue (443C81) on metabisulphite induced broncoconstriction and intradermal histamine flare in healthy volunteers. Br J Clin Pharmacol 1991; 32: 663.
19. Wootton R. Compounds designed to bind to haemoglobin. In The design of drugs to macromolecular targets, ed Beddell CR, John Wiley and Sons Ltd, London, 1992.
20. Rolan PE. The exploratory clinical development of tucaresol, an antisickling agent, using a novel surrogate marker. MD thesis, University of Adelaide, Adelaide, 1995.
21. Rolan PE, Parker JE, Gray SJ, et al. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Br J Clin Pharmacol 1993; 35: 419-425.
22. Rolan PE, Mercer AJ, Wootton R, Posner J. Pharmacokinetics and pharmacodynamics of multiple oral doses of tucaresol, an anti-sickling agent, in healthy volunteers. Br J Clin Pharmacol 1995; 39: 375-380.
23. Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia. Br J Haematol 1996; 93: 817-821.
24. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991; 40: 169-173.
25. Deakin JFW, Guimaraes FS, Graeff FG. Testing 5HT theories of anxiety in normal volunteers. In Strategies for studying brain disorders Volume 1 Depressive, anxiety and drug abuse disorders, eds Palomo T and Archer T, London: Farrand Press, 1994: 211-238.
26. Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993; 32 (Suppl 3): 3-8.
27. Rathburn RC. Surrogate markers for assessing treatment response in HIV disease. Ann Pharmacother 1993; 27: 450-455.
28. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis 1993; 16 (Suppl 1): S22-25.
29. O'Connor BJ, Ridge SM, Chen-Worsdell YM, Uden S, Barnes PJ, Chung KF. Complete inhibition of airway and neutrophil response to inhaled platelet activating factor (PAF) by a novel PAF antagonist UK-74,506. Am Rev Resp Dis 1991; 143: A156.
30. Kuitert CM, Hui KP, Uthatarkumar S, et al. Effect of the platelet activating factor antagonist UK-74,506 on the early and late response to allergen. Am Rev Resp Dis 1993; 147: 82-88.
31. Kuitert CM, Angus RM, Barnes NC, et al. Effect of a novel platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 1995; 151: 1331-1335.
32. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 1989; 8: 414-425.
33. Manna VK, Marks P, Gibson JR. An evaluation of the antihistamine activity of acrivastine and its onset in human skin. J Int Med Res 1992; 20: 106-111.
34. Minton N, Swift R, Lawlor C, et al. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity. Clin Pharmacol Ther 1993; 54: 53-57.
35. Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4-induced bronchocontriction in subjects with asthma: a concentration-effect study. Clin Pharmacol Ther 1993; 54: 430-436.
36. Wesnes K, Simpson PM, Christmas L. A microcomputerised system for evaluating the cognitive actions of drugs in the young, elderly and demented. Eur J Clin Pharmacol 1989; 36: A38.
37. Wesnes K, Simpson PM. Can scopolamine produce a model of the memory deflates seen in memory and aging? In Practical aspects of memory: current research and issues: Volume 2: Clinical and educational implications, eds Gruneberg MM, Morris PE, Sykes RN, Chichester: Wiley, 1988.
38. Davis JR. Laboratory methods for the conduct of experimental malaria challenge of volunteers. Vaccine 1994; 12: 321-327.
39. Posner J, Telekes A, Crowley D, et al. Effects of an opiate on cold-induced pain and the CNS in healthy volunteers. Pain 1985; 23: 73-82.
40. The CAST investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.